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Abstract 
Lipid emulsions are widely used for the treatment of systemic toxicity that arises from local an-
esthetics. The goal of this in vitro study was to examine the cellular mechanism associated with the 
lipid emulsion-mediated attenuation of vasodilation induced by a toxic dose of bupivacaine in 
isolated endothelium-denuded rat aorta. The effects of lipid emulsion on vasodilation induced by 
bupivacaine, mepivacaine, and verapamil were assessed in isolated aorta precontracted with 
phenylephrine, the Rho kinase stimulant NaF, and the protein kinase C activator phorbol 
12,13-dibutyrate (PDBu). The effects of Rho kinase inhibitor Y-27632 on contraction induced by 
phenylephrine or NaF were assessed. The effects of bupivacaine on intracellular calcium con-
centrations ([Ca2+]i) and tension induced by NaF were simultaneously measured. The effects of 
bupivacaine alone and lipid emulsion plus bupivacaine on myosin phosphatase target subunit 1 
(MYPT1) phosphorylation induced by NaF were examined in rat aortic vascular smooth muscle 
cells. In precontracted aorta, the lipid emulsion attenuated bupivacaine-induced vasodilation but 
had no effect on mepivacaine-induced vasodilation. Y-27632 attenuated contraction induced by 
either phenylephrine or NaF. The lipid emulsion attenuated verapamil-induced vasodilation. 
Compared with phenylephrine-induced precontracted aorta, bupivacaine-induced vasodilation 
was slightly attenuated in NaF-induced precontracted aorta. The magnitude of the bupiva-
caine-induced vasodilation was higher than that of a bupivacaine-induced decrease in [Ca2+]i. Bu-
pivacaine attenuated NaF-induced MYPT1 phosphorylation, whereas lipid emulsion pretreatment 
attenuated the bupivacaine-induced inhibition of MYPT1 phosphorylation induced by NaF. Taken 
together, these results suggest that lipid emulsions attenuate bupivacaine-induced vasodilation via 
the attenuation of inhibition of MYPT1 phosphorylation evoked by NaF. 
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Introduction 
Lipid emulsions are effective treatments for car-
diac arrest caused by toxic doses of bupivacaine and 
levobupivacaine [1,2]. In addition, lipid emulsions 
such as SMOFlipid®, Intralipid®, and Lipofundin® 
MCT/LCT (medium-chain triglycride and long-chain 
triglyceride) reverse severe vasodilation induced by 
toxic doses of levobupivacaine and bupivacaine, 
suggesting that lipid emulsions are involved in the 
recovery of vascular tone from vascular collapse 
caused by toxic doses of bupivacaine and levobupi-
vacaine via the sequestration of local anesthetics in a 
lipid solubility dependent manner [3-5]. The pro-
posed mechanisms of lipid emulsion therapy include 
lipid sink (sequestration of local anesthetic), fatty acid 
supply, reversal of sodium channel blockade, cyto-
protection, calcium entry and pharmacokinetic effect 
[2]. 
Low doses of levobupivacaine produce vaso-
constriction at the resting tension, whereas high doses 
of levobupivacaine cause vasodilation, which appears 
to be associated with vascular collapse evoked by 
such high doses of levobupivacaine [6-8]. In addition, 
a toxic dose of bupivacaine induces vasodilation that 
appears to be partially associated with decreased cal-
cium sensitization in isolated endothelium-denuded 
rat aorta precontracted with phenylephrine [9]. Ago-
nists, including phenylephrine, activate Rho kinase 
and protein kinase C (PKC), which leads to contrac-
tion via increased calcium sensitization [10]. Rho ki-
nase and PKC phosphorylate myosin phosphatase 
target subunit 1 (MYPT1) and phosphoryla-
tion-dependent inhibitory protein of myosin phos-
phatase, respectively, leading to increased calcium 
sensitization via the inhibition of myosin light chain 
phosphatase (MLCP) [10]. Because the phosphoryla-
tion of MYPT1, which is a signaling molecule down-
stream of Rho kinase that participates in vascular 
smooth muscle contraction, is involved in calcium 
sensitization, whereas bupivacaine-induced vasodila-
tion causes decreased calcium sensitization, we tested 
the hypothesis that lipid emulsion attenuated bupi-
vacaine-induced vasodilation via the modulation of 
MYPT1 phosphorylation [3-5,9,10]. The goal of this in 
vitro study was to investigate the cellular mechanism 
responsible for the lipid emulsion-mediated attenua-
tion of severe vasodilation induced by a toxic dose of 
bupivacaine, focusing on MYPT1 phosphorylation. 
The severe vasodilation was induced by a toxic dose 
of bupivacaine in isolated endothelium-denuded rat 
aortas precontracted with vasoconstrictors such as 
phenylephrine or the Rho kinase activator, NaF.  
 
 
Materials and methods 
All experimental procedures and protocols were 
approved by the Institutional Animal Care and Use 
Committee at Gyeongsang National University. All 
experimental procedures were performed in accord-
ance with the Guide for the Care and Use of Labora-
tory Animals prepared by the Institute for Laboratory 
Animal Research. 
Preparation of aortic rings for tension meas-
urements  
Preparation of aortic rings for tension measure-
ments was performed as previously described [4]. 
Male Sprague-Dawley rats weighing 250–300 g were 
anesthetized by intramuscular injection of zoletil 50 
(15 mg/kg, Virbac Laboratories, Carros, France). The 
descending thoracic aorta was dissected free of sur-
rounding connective tissues and fat under micro-
scopic guidance in a Krebs solution bath consisting of 
118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 2.4 mM CaCl2, 25 mM NaHCO3, and 11 mM 
glucose. The endothelium was removed from all aor-
tic rings by inserting a 25-gauge needle into the lumen 
of the rings and gently rubbing the ring for a few 
seconds. The aorta was suspended on a Grass isomet-
ric transducer (FT-03, Grass Instrument, Quincy, MA, 
USA) under a 3.0-g resting tension in a bath contain-
ing 10 mL Krebs solution at 37°C and aerated con-
tinuously with 95% O2 and 5% CO2 to maintain the pH 
between 7.35–7.45. The rings were equilibrated at a 
3.0-g resting tension for 120 min, and the bath solution 
was changed every 30 min. After contractions in-
duced by 10-8 M phenylephrine had stabilized, endo-
thelial denudation of the aortic rings was verified by 
observation of less than 15% relaxation in response to 
acetylcholine (10-5 M). After washing out the phe-
nylephrine from the organ bath and allowing a return 
of the isometric tension to baseline, the main experi-
ments were performed according to the experimental 
protocols described below. Each ring was used for 
only one concentration-response curve induced by 
bupivacaine, mepivacaine, verapamil, phenylephrine, 
or NaF. Because increase in left ventricular systolic 
pressure by lipid emulsion seems to be associated 
with the blockade of nitric oxide in an in vivo state 
with endothelium-intact aorta, the Krebs solution 
contained the nitric oxide synthase inhibitor 
NW-nitro-L-arginine methyl ester (L-NAME, 10-4 M) to 
prevent the release of endogenous nitric oxide from 
the residual endothelium [11]. 
Experimental protocols 
The first series of experiments was designed to 
examine the effects of lipid emulsions (Intralipid®, 
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0.35 and 0.8%) on the vasodilation induced by bupi-
vacaine or mepivacaine in endothelium-denuded 
aorta precontracted with phenylephrine or NaF. Lipid 
emulsions (0.35 and 0.8%) were added into the organ 
bath for 20 min before the addition of phenylephrine 
(10-6 M) or NaF (8 × 10-3 M). After the phenylephrine- 
or NaF-induced contraction had stabilized, incre-
mental concentrations of bupivacaine (10-6 to 10-3 M) 
or mepivacaine (10-5 to 10-2 M) were added to the or-
gan bath to generate concentration-response curves 
[12]. In addition, we examined the effects of the lipid 
emulsion (Intralipid®, 0.35 and 0.8%) alone on con-
traction induced by phenylephrine (10-6 M) or NaF (8 
× 10-3 M) in isolated endothelium-denuded aorta. Af-
ter the contraction induced by NaF or phenylephrine 
stabilized in isolated endothelium-denuded aorta, the 
lipid emulsion (0.35 and 0.8%) was added to the organ 
bath to examine changes in tension induced by NaF or 
phenylephrine.  
The second series of experiments was designed 
to examine the effect of Rho kinase inhibitor Y-27632 
on the contraction induced by phenylephrine (10-6 M) 
or NaF (8 × 10-3 M) in endothelium-denuded aorta. 
After phenylephrine- or NaF-induced contraction had 
stabilized, one of three different concentrations of 
Y-27632 (10-6, 3 × 10-6, and 10-5 M) was directly added 
to the organ bath, and the tension was continuously 
measured for 60 min.  
The third series of experiments was designed to 
examine the effects of various vasoconstrictors on 
bupivacaine-induced vasodilation in endotheli-
um-denuded aorta. After contraction induced by 
phenylephrine (10-6 M), NaF (8 ×10-3 M), and PKC 
activator phorbol 12,13-dibutyrate (PDBu, 10-6 M) had 
stabilized, incremental concentrations (10-6 to 10-3 M) 
of bupivacaine were added to the organ bath to com-
pare the patterns of bupivacaine-induced vasodilation 
in aorta precontracted with the various vasoconstric-
tors. 
Finally, we investigated the effects of the lipid 
emulsion (Intralipid®, 0.25%) on vasodilation induced 
by verapamil (a highly lipid soluble calcium channel 
blocker) in aorta precontracted with phenylephrine to 
examine whether the lipid emulsion-mediated atten-
uation of bupivacaine-induced vasodilation is specific 
or nonspecific [13]. The lipid emulsion was added to 
the organ bath for 20 min before the addition of phe-
nylephrine (10-7 M). After the phenylephrine-induced 
contraction had reached a plateau, incremental con-
centrations of verapamil (10-9 to 10-5 M) were added to 
the organ bath to generate verapamil dose-response 
curves. 
Fura-2 loading and simultaneous measure-
ments of intracellular calcium concentration 
([Ca2+]i) and tension  
[Ca2+]i and tension were simultaneously meas-
ured as described previously [9,14]. Muscle strips 
were exposed to the acetoxymethyl ester of fura-2 
(fura-2/AM, 10 µM) in the presence of 0.02% cremo-
phor EL for 5–6 h at room temperature. After loading, 
a muscle strip was washed with Krebs solution at 
37°C for 20 min to remove any uncleaved fura-2/AM 
and held horizontally in a temperature controlled, 
7-ml organ bath. One end of the muscle strip was 
connected to a force-displacement transducer 
(MLT050, AD Instruments, Colorado Springs, CO, 
USA) to monitor muscle contraction. The muscle strip 
was illuminated alternately (48 Hz) at two excitation 
wavelengths (340 and 380 nm). The intensity of the 
500-nm fluorescence (F340 and F380) was measured 
with a fluorometer (CAF-110, Jasco, Tokyo, Japan). 
The ratio of F340 to F380 (F340/F380) was calculated 
as an indicator of [Ca2+]i. Therefore, the ratio 
(F340/F380) and tension obtained from 8 × 10-3 M 
NaF-stimulated aortic strips were taken as 100 and 
100%, respectively. Isometric contractions and the 
ratio of F340/F380 were recorded with a Pow-
erLab/400 using the chart program (AD instruments). 
Muscle strips were placed under an initial 3.0-g rest-
ing tension. All strips that came from the same animal 
were used in different experimental protocols. When 
both [Ca2+]i and contraction induced by 8 × 10-3 M NaF 
reached steady-state levels, incremental concentra-
tions of bupivacaine (10-6 to 10-3 M) were added cu-
mulatively. 
Cell culture 
Vascular smooth muscle cells (VSMCs) were 
isolated from thoracic aorta of male rats by enzymatic 
dissociation and grown in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% heat- 
inactivated fetal bovine serum, 2 mM L-glutamine, 100 
U/ml penicillin, and 100 µg/ml streptomycin as de-
scribed previously [14]. Cells were subcultured twice 
per week by harvesting with trypsin/ethylenedia-
minetetraacetic acid and seeding into flasks at a den-
sity of 7.5 × 105/mm2. For experiments, cells between 
passage numbers 2 and 10 were seeded into dishes 
(107/100-mm dish), fed every other day, and used at 
confluence (6–7 days). Cells were deprived of serum 
overnight prior to treatment. 
Western blot analysis  
Western blot analysis was performed as de-
scribed previously [14]. Cells were lysed in 
PRO-PREP protein extract solution (iNtRON Bio-
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technology, Houston, TX, USA) to obtain total cell 
lysates, and the lysates were centrifuged at 100,000 × g 
for 20 min at 4°C. Protein concentrations were deter-
mined using the Bradford method. For preparation of 
sample loading, equal volumes of 2× sodium dodecyl 
sulfate sample buffer (0.1 mol/L Tris-HCI, 20% glyc-
erol, 4% sodium dodecyl sulfate, and 0.01% bromo-
phenol blue) and supernatant fractions from the ly-
sates were mixed. Proteins (60 µg) were separated by 
10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis for 90 min at 110 V. The separated pro-
teins were transferred onto polyvinylidene difluoride 
membranes for 2 h at 20 mA using SD Semi-dry 
Transfer Cells (Bio-Rad Laboratories, Hercules, CA, 
USA). After blocking the membranes using 5% nonfat 
milk in Tris-buffed saline (pH 7.0), the membranes 
were incubated overnight at 4°C with primary anti-
bodies (anti-phospho-MYPT1 and anti-MYPT1 anti-
bodies) at a dilution of 1:500 in 5% skim milk in 
Tris-buffed saline containing Tween-20. Bound anti-
body was detected with horseradish peroxi-
dase-conjugated anti-mouse IgM. Membranes were 
washed and developed using the Western Blotting 
Luminol Reagent system (iNtRON Biotechnology) 
and autoradiography.  
Materials 
All drugs were of the highest purity available 
commercially. Phenylephrine, NaF, PDBu, acetylcho-
line, and L-NAME were obtained from Sigma Aldrich 
(St. Louis, MO, USA). Y-27632 was obtained from 
Calbiochem (La Jolla, CA, USA). Fura-2/AM was ob-
tained from Molecular Probes (Eugen, OR, USA). An-
ti-phospho-MYPT1 and anti-MYPT1 antibodies were 
obtained from Cell Signaling Technology (Beverly, 
MA, USA). Intralipid® 20% was obtained from Frese-
nius Kabi Korea (Seoul, Korea). Bupivacaine was ob-
tained from Reyon Pharmaceutical Co., Ltd. (Seoul, 
Korea). Mepivacaine was donated by Hana Pharma-
ceutical Co., Ltd. (Gyeonggi-do, Korea). All concen-
trations except the lipid emulsions were expressed as 
the final molar concentration in the organ bath. PDBu 
and fura-2/AM were dissolved in dimethyl sulfoxide 
(final organ bath concentration: 0.01%). Unless stated 
otherwise, all drugs were dissolved in distilled water. 
Data analysis 
The values are shown as the mean ± SD. Vaso-
dilation induced by bupivacaine, mepivacaine, 
Y-27632, and verapamil is expressed as the percentage 
of the maximum contraction induced by phe-
nylephrine, NaF, and PDBu. The effect of the lipid 
emulsion on vasodilation induced by bupivacaine or 
mepivacaine in endothelium-denuded aorta precon-
tracted with phenylephrine or NaF was analyzed us-
ing two-way repeated measures analysis of variance 
(ANOVA) followed by Bonferroni’s post-test (Prism 
5.0, GraphPad Software, San Diego, CA, USA). The 
effect of the lipid emulsion alone on contraction in-
duced by phenylephrine or NaF in endotheli-
um-denuded aorta was analyzed using two-way re-
peated measures ANOVA followed by Bonferroni’s 
post-test. The logarithm of drug concentration (ED50) 
producing 50% of the maximal relaxation induced by 
verapamil was calculated with nonlinear regression 
analysis by fitting the concentration-response rela-
tionship for verapamil to a sigmoidal curve using 
commercially available software (Prism 5.0, 
GraphPad Software). Statistical analysis for the com-
parison of ED50 and maximal relaxation between the 
control and lipid emulsion-treated groups during 
verapamil-induced relaxation was performed using 
Mann-Whitney U test. The effects of vasoconstrictors 
on bupivacaine-induced vasodilation and of Y-27632 
on contraction induced by phenylephrine and NaF 
were analyzed using two-way repeated measures 
ANOVA followed by Bonferroni’s post-test. Analyses 
regarding effects of bupivacaine alone and lipid 
emulsion plus bupivacaine on the NaF-induced 
MYPT1 phosphorylation were performed using 
one-way ANOVA followed by Bonferroni’s post-test. 
The effect of bupivacaine on the tension and [Ca2+]i 
induced by NaF was analyzed using two-way re-
peated measures ANOVA followed by Bonferroni’s 
post-test. Scanning densitometry was performed us-
ing an Image Master VSD (Pharmacia Biotech, San 
Francisco, CA, USA). P values less than 0.05 were sta-
tistically significant. 
Results 
The lipid emulsion (0.35 and 0.8%) attenuated 
bupivacaine-induced vasodilation in endotheli-
um-denuded aorta precontracted with phenylephrine 
(Fig. 1A; P < 0.05 versus control at 3 × 10-4 M bupiva-
caine). However, the lipid emulsion had no effect on 
mepivacaine-induced vasodilation under similar 
conditions (Fig. 2A). In addition, in endotheli-
um-denuded aorta precontracted with NaF, the lipid 
emulsion (0.35 and 0.8%) attenuated bupiva-
caine-induced vasodilation in a concentra-
tion-dependent manner (Fig. 1B; P < 0.05 versus con-
trol at 10-4 and 3 × 10-4 M bupivacaine), whereas the 
lipid emulsion had no effect on mepivacaine-induced 
vasodilation (Fig. 2B). The lipid emulsion (0.35 and 
0.8%) had no significant effect on aorta precontracted 
with NaF (8 × 10-3 M) or phenylephrine (10-6 M) 
compared with time-matched controls (data not 
shown). All doses (10-6 to 10-5 M) of Y-27632 attenu-
ated phenylephrine-induced contraction in endothe-
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lium-denuded aorta (Fig. 3A; P < 0.01 versus control 
at 20 to 60 min) as well as NaF-induced contraction 
(Fig. 3B; P < 0.001 versus control at 10 to 60 min). Bu-
pivacaine-induced vasodilation was slightly attenu-
ated in NaF-induced precontracted aorta compared 
with phenylephrine-induced precontracted aorta (Fig. 
4; P < 0.05 versus phenylephrine at 3 × 10-5 and 3 × 10-4 
M bupivacaine), whereas bupivacaine-induced vaso-
dilation was greatly attenuated in PDBu-induced 
precontracted aorta compared with phe-
nylephrine-induced precontracted aorta (Fig. 4; P < 
0.05 versus phenylephrine at 3 × 10-5 to 10-3 M bupi-
vacaine). The lipid emulsion (0.25%) attenuated ve-
rapamil-induced vasodilation in aorta precontracted 
with phenylephrine (Fig. 5; ED50: P < 0.05 versus con-
trol). 
 
 
Figure 1. Effects of lipid emulsions (Intralipid®, 0.35 and 0.8%) on bupivacaine-induced vasodilation in isolated endothelium-denuded aorta precontracted with 10-6 M phe-
nylephrine (A) or 8 × 10-3 M NaF (B). All values are shown as the mean ± SD (n = 6) and expressed as the percentage of the maximal contraction induced by phenylephrine or 
NaF. N indicates the number of rats from which descending thoracic aortic rings were derived. A: *P < 0.05, †P < 0.01, and ‡P < 0.001 versus control. B: *P < 0.05, †P < 0.01, and 
‡P < 0.001 versus control. #P <0.001 versus 0.35% Intralipid®.  
 
 
Figure 2. Effects of lipid emulsions (Intralipid®, 0.35 and 0.8%) on mepivacaine-induced vasodilation in isolated endothelium-denuded aorta precontracted with 10-6 M phe-
nylephrine (A) or 8 × 10-3 M NaF (B). All values are shown as the mean ± SD (n = 5) and expressed as the percentage of the maximal contraction induced by phenylephrine or 
NaF. N indicates the number of rats from which descending thoracic aortic rings were derived. 
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 Figure 3. A: Effects of Y-27632 on phenylephrine (10-6 M)-induced contraction in isolated endothelium-denuded aorta. All values are shown as the mean ± SD (n = 7) and 
expressed as the percentage of the maximal contraction induced by phenylephrine. N indicates the number of rats from which descending thoracic aortic rings were derived. *P 
< 0.01 and †P < 0.001 versus control. B: Effects of Y-27632 on NaF (8 × 10-3 M)-induced contraction in isolated endothelium-denuded aorta. All values are shown as the mean 
± SD (n = 6) and expressed as the percentage of the maximal contraction induced by NaF. N indicates the number of descending thoracic aortic rings. *P < 0.001 versus control.  
 
Figure 4. Bupivacaine-induced vasodilation in isolated endothelium-denuded aorta precontracted with 10-6 M phenylephrine, 8 × 10-3 M NaF, and phorbol 12,13-dibutyrate 
(PDBu, 10-6 M). All values are shown as the mean ± SD (n = 6) and expressed as the percentage of the maximal contraction induced by phenylephrine, NaF, and PDBu. N indicates 
the number of rats from which descending thoracic aortic rings were derived. *P < 0.05 and †P < 0.001 versus phenylephrine.  
 
The magnitude of bupivacaine-induced vasodi-
lation was higher than that of the bupiva-
caine-induced decrease in [Ca2+]i in aorta precon-
tracted with 8 × 10-3 M NaF (Fig. 6; P < 0.001 versus 
F340/F380 at 3 × 10-5 to 10-3 M bupivacaine).  
NaF (8 × 10-3 M) induced MYPT1 phosphoryla-
tion in rat aortic VSMCs (Fig. 7; P < 0.001 versus con-
trol). Bupivacaine (3 × 10-4 M) attenuated 
NaF-induced MYPT1 phosphorylation (Fig. 7; P< 0.01 
versus NaF alone), whereas the lipid emulsion (0.8%) 
inhibited the bupivacaine-induced attenuation of 
MYPT1 phosphorylation evoked by NaF (Fig. 7; P < 
0.05 versus combined treatment with bupivacaine and 
NaF). 
Discussion 
This is first study to suggest that lipid emulsions 
attenuate vasodilation induced by a toxic dose of bu-
pivacaine via the attenuation of the inhibition of 
MYPT1 phosphorylation induced by bupivacaine. The 
major findings of this in vitro study are as follows: 1) 
The lipid emulsion attenuates vasodilation induced 
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by a toxic dose of bupivacaine in isolated aorta pre-
contracted with phenylephrine or NaF, but had no 
effect on vasodilation induced by a toxic dose of 
mepivacaine; 2) the magnitude of bupiva-
caine-induced vasodilation slightly differed in iso-
lated aorta precontracted with phenylephrine or NaF; 
3) the magnitude of bupivacaine-induced vasodilation 
was higher than that of the bupivacaine-induced de-
crease in [Ca2+]i in NaF-stimulated aortic strips; and 4) 
the lipid emulsion inhibited the bupivacaine-induced 
attenuation of MYPT1 phosphorylation induced by 
NaF.  
 
 
Figure 5. Effects of the lipid emulsion (Intralipid®, 0.25%) on verapamil-induced vasodilation in isolated endothelium-denuded aorta precontracted with 10-7 M phenylephrine. All 
values are shown as the mean ± SD (n = 5) and expressed as the percentage of the maximal contraction induced by phenylephrine. N indicates the number of rats from which 
descending thoracic aortic rings were derived. ED50: *P < 0.05 versus control.  
 
Figure 6. A: Effects of bupivacaine on NaF (8 x 10-3 M)-stimulated intracellular calcium concentration ([Ca2+]i) (upper trace) and muscle tension (lower trace) in endotheli-
um-denuded rat thoracic aortic strips. The [Ca2+]i of fura-2-loaded aortic strips was detected using a fluorometer and expressed as the ratio F340/F380. The value 100% 
represents the NaF (8 x 10-3 M)-induced increases in both [Ca2+]i and muscle tension before the cumulative addition of bupivacaine. When [Ca2+]i and muscle tension induced by 
8 × 10-3 M NaF had reached steady-state levels, incremental concentrations of bupivacaine (10-6 to 10-3 M) were cumulatively added. WO: washout. B: Cumulative concentra-
tion-response curve for bupivacaine in NaF (8 × 10-3 M)-stimulated endothelium-denuded rat thoracic aortic strips. Incremental concentrations (10-6 to 10-3 M) of bupivacaine 
were cumulatively added during the sustained increases in both [Ca2+]i and tension induced by NaF (8 × 10-3 M). The value 100% represents the NaF (8 × 10-3 M)-induced increase 
in both [Ca2+]i and muscle tension before the cumulative addition of bupivacaine. Each point represents the mean of five experiments, and SD is shown by vertical bars. *P < 0.001 
versus F340/F380. 
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Figure 7. The effects of bupivacaine alone and lipid emulsion (Intralipid®, 0.8%) plus bupivacaine on NaF-induced myosin phosphatase target subunit 1 (MYPT1Thr696) phos-
phorylation in rat aortic vascular smooth muscle cells (VMSCs). VSMCs were treated with 8 × 10-3 M NaF alone for 30 min, pretreatment with 3 × 10-4 M bupivacaine for 30 min, 
followed by 8 × 10-3 M NaF for 30 min, and pretreatment with 0.8% lipid emulsion for 30 min, followed by post-treatment with 3 × 10-4 M bupivacaine for 30 min and a subsequent 
30-min treatment with 8 × 10-3 M NaF. Phosphorylation of MYPT1 on Thr696 was examined by western blot analysis as described in the methods. Data are expressed as the mean 
± SD (n = 3). N indicates the number of independent experiments. *P < 0.001 versus control. †P < 0.01 versus 8 × 10-3 M NaF alone. #P < 0.05 versus 3 × 10-4 M bupivacaine plus 
8 × 10-3 M NaF. p-MYPT1Thr696: phosphorylated MYPT1Thr696, t-MYPT1: total MYPT1. 
 
Agonists including phenylephrine produce con-
traction mediated by calcium sensitization, which 
implies a higher increase in tension than in [Ca2+]i 
[10]. Calcium sensitization mediated by PKC or Rho 
kinase inhibits MLCP via direct inhibition of MLCP or 
phosphorylation of MYPT1, leading to increased 
phosphorylation of regulatory light chain of myosin 
(MLC) and enhanced contraction [10]. The magnitude 
of bupivacaine-induced relaxation slightly differed in 
contracted aorta induced by either phenylephrine or 
NaF (Fig. 4). However, the magnitude of bupiva-
caine-induced relaxation was greatly lowered in 
PDBu-induced precontracted aorta than in phe-
nylephrine-induced precontracted aorta (Fig. 4). In 
agreement with a previous report, Y-27632 attenuated 
contraction induced by phenylephrine and NaF (Fig. 
3) [12]. Taken together, bupivacaine-induced vasodi-
lation appears to be associated with the inhibition of 
contraction mediated by a pathway involving Rho 
kinase in isolated aorta precontracted with NaF or 
phenylephrine [12].  
In agreement with a previous study, the lipid 
emulsion attenuated bupivacaine-induced vasodila-
tion in aorta precontracted with phenylephrine but 
had no effect on mepivacaine-induced vasodilation 
[15]. It has been reported that lipid emulsions reverse 
vasodilation induced by toxic doses of bupivacaine 
and levobupivacaine, but have no effects on vasodila-
tion induced by a toxic dose of mepivacaine, sup-
porting the lipid sink theory that states that lipid 
emulsions extract high levels of highly lipid soluble 
local anesthetics from tissues [2-4]. Similar to previous 
reports, the lipid emulsion attenuated bupiva-
caine-induced vasodilation in aorta precontracted 
with NaF, but had no effect on mepivacaine-induced 
vasodilation [3,4,15]. In addition, lipid emulsion pre-
treatment allows effective recovery from bupiva-
caine-induced cardiac toxicity in an isolated rat heart 
model, but not from mepivacaine-induced cardiac 
toxicity [16]. Post-treatment with lipid emulsions re-
duces heart rate recovery time from cardiac arrest 
induced by bupivacaine but not by mepivacaine [17]. 
These previous studies suggest that the potency of 
lipid emulsion-mediated scavenging effects of local 
anesthetics may be dependent on their lipid solubility 
(lipid/water partition coefficient: bupivacaine [27.5] 
versus mepivacaine [0.8]) [16-18]. Furthermore the 
lipid emulsion itself had no effect on contraction in-
duced by NaF or phenylephrine, suggesting that the 
lipid emulsion has no effect on Rho kinase-mediated 
contraction induced by NaF or phenylephrine. Taking 
previous reports and current results into considera-
tion, one of the putative mechanisms responsible for 
the lipid emulsion-mediated attenuation of bupiva-
caine-induced vasodilation can be explained as fol-
lows [3,4,15-18]. As the lipid solubility of bupivacaine 
is higher than that of mepivacaine, the lipid emulsion 
can extract higher amounts of bupivacaine than 
mepivacaine, leading to enhanced lipid emul-
sion-mediated attenuation of bupivacaine-induced 
Int. J. Med. Sci. 2015, Vol. 12 
 
http://www.medsci.org 
966 
vasodilation. In other words, the lipid emul-
sion-mediated attenuation of vasodilation induced by 
a toxic dose of bupivacaine appears to be associated 
with the relatively high lipid solubility of bupiva-
caine. However, lipid emulsion reverses the mepiva-
caine-induced blockade of the fast sodium current in 
cardiomyocytes [19]. This difference between previ-
ous and current studies may be ascribed to difference 
in the concentration of lipid emulsion (0.8 versus 10%), 
specimen (aorta versus cardiomyocyte) and experi-
mental method (isometric tension measurement ver-
sus whole cell patch clamp). As contraction induced 
by phenylephrine and NaF was attenuated by Y-27632 
(Fig. 3), the lipid emulsion-mediated attenuation of 
vasodilation in precontracted aorta seems to be asso-
ciated with the attenuation of the inhibitory effects of 
a toxic dose of bupivacaine on the Rho ki-
nase-mediated pathway contributing to vascular 
smooth muscle contraction [12]. Bupivacaine-induced 
vasodilation in aorta precontracted with phe-
nylephrine is mediated partially by decreased calcium 
sensitization [9]. Similar to results of a previous study, 
using aortic strips stimulated by NaF, bupiva-
caine-induced vasodilation was enhanced compared 
with the bupivacaine-induced decrease in [Ca2+] (Fig. 
6), suggesting that decreased calcium sensitization 
partially contributes to the vasodilation via the inhi-
bition of the Rho kinase-MYPT1 pathway induced by 
a toxic dose of bupivacaine [9,10]. As the lipid emul-
sion inhibited vasodilation induced by at toxic dose of 
verapamil (Fig. 5), the attenuation of vasodilation may 
be associated with the nonspecific inhibitory action of 
the lipid emulsion on bupivacaine-induced vasodila-
tion [13].  
In order to confirm that the lipid emulsion at-
tenuates bupivacaine-induced vasodilation via the 
attenuation of the inhibition of the pathway involving 
Rho kinase and MYPT1, we examined the effects of 
bupivacaine alone and lipid emulsion plus bupiva-
caine on NaF-induced MYPT1 phosphorylation using 
western blotting. In agreement with a previous report, 
NaF induced MYPT1 phosphorylation in rat aortic 
VSMCs [12]. The phosphorylation of MYPT1Thr696 in-
duced by Rho kinase inhibits MLCP, leading to the 
enhanced phosphorylation of MLC and increased 
contraction [10,20]. In the current study, a toxic dose 
(3 × 10-4 M) of bupivacaine, which exceeds the ap-
proximate serum concentration (10-5 M) of bupiva-
caine that produces hypotension caused by bupiva-
caine-induced systemic toxicity, attenuated 
NaF-induced MYPT1 phosphorylation, whereas the 
lipid emulsion attenuated the bupivacaine-mediated 
inhibition of MYPT1 phosphorylation induced by NaF 
[21]. Taken together with previous reports and results 
from isometric tension measurements, the lipid 
emulsion-mediated attenuation of the inhibition of 
MYPT1 phosphorylation induced by a toxic dose of 
bupivacaine appears to contribute to the attenuation 
of vasodilation [10,20]. Further studies of the signal-
ing pathway downstream of the lipid emul-
sion-mediated attenuation of the inhibition of the 
pathway involving Rho kinase and MYPT1 are 
needed to elucidate a detailed cellular signaling 
pathway.  
The clinical relevance of the lipid emul-
sion-mediated attenuation of vasodilation induced by 
a toxic dose of bupivacaine should be carefully inter-
preted. The limitations of the current study are as 
follows: First, we used aorta, regarded as a conduit 
vessel, whereas small, resistance arterioles primarily 
contribute to the total peripheral vascular resistance, 
which is regarded as one of the most important de-
terminants of blood pressure [22]. Second, we used 
endothelium-denuded aorta, whereas endotheli-
um-derived vasodilators, including nitric oxide, en-
dothelium-derived hyperpolarizing factor, and pros-
tacyclin, modulate the vascular response [23]. Third, 
the lipid emulsion itself increases left ventricular 
systolic pressure via the blockade of nitric oxide re-
lease [11]. In addition, triglyceride microemul-
sion-induced reversal of bupivacaine toxicity is me-
diated by numerous factors, including scavenging 
and cardiotonic effects, fatty acid oxidation and drug 
redistribution [24,25]. Even with the above-mentioned 
factors that may modify the current results, the lipid 
emulsion may provide beneficial effects for recovery 
of vascular tone from vascular collapse induced by a 
toxic dose of bupivacaine.  
In conclusion, these results suggest that lipid 
emulsions attenuate vasodilation induced by a toxic 
dose of bupivacaine via the attenuation of the inhibi-
tion of MYPT1 phosphorylation in isolated endothe-
lium-denuded rat aorta. This effect appears to be as-
sociated with the high lipid solubility of bupivacaine. 
Abbreviation 
MYPT1: myosin phosphatase target subunit 1; 
PDBu: phorbol 12,13-dibutyrate; PKC: protein kinase 
C; MLC: regulatory light chain of myosin; MLCP: 
myosin light chain phosphatase; VSMC: vascular 
smooth muscle cell; [Ca2+]i: intracellular calcium con-
centration. 
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